Madrid, Spain: The vast majority of measles cases in Europe were reported in unvaccinated patients, and children younger than two years old were at a higher risk of dying from measles than older patients, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) .
Presenting author Dr Emmanuel Robesyn of the European Centre for Disease Prevention and Control (ECDC) in Stockholm said they analysed data to support European states in reaching the recommended 95% two-dose vaccination coverage. It also set out to determine any possible differences between society's youngest individuals and older populations when infected with the disease.
The study examined all 37,365 measles cases reported to the ECDC from 1 January 2013 through 31 December 2017. The researchers found 81% of all reported cases were patients who were not vaccinated. Most cases were in Italy, Romania, Germany, the Netherlands and the United Kingdom, with each reporting more than 5% of the cases. These countries also had the most cases that had not been connected with importation of the disease.
The study also noted that 33% of the patients were hospitalised and 11% had pneumonia. Most cases, 81%, involved those who were two years old and older. Of the remaining 19% share, 9% were one year old and 10% younger than one year.
The rate at which patients died from the disease highlighted the impact measles had on the very youngest populations. ECDC's analysis showed that one in 1,000 measles patients died, and of those, the greatest fatality was seen in the youngest cases. Cases in one-year-olds were six times more likely to die compared with cases of patients who were two years old or older. Cases in infants younger than one year were seven times more likely to die.
The findings are based on ECDC data collected in the most recent years in the EU/EEA, which can benefit communication efforts to tackle resurgence of measles in Europe.
The World Health Organization has set goals for the elimination of measles and rubella. One of the main actions to achieve those goals is to maintain high rates of sustained immunizations.
Abstract no: O0060, How does the outcome of measles cases under one year of age differ from that of older cases, EU/EEA 2013 – 2017; session People, microorganisms and the environment 09:45 – 10:45, Saturday, 21 April 2018, Hall K
 The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). This year it will take place from 21 – 24 April 2018 in Madrid, Spain. At the world's largest congress combining the fields of infectious diseases and clinical microbiology, researchers will present more than 3,000 regular and late-breaking abstracts with the latest findings and recommendations, which are set to help improve diagnosis, prevention and treatment of infection-related diseases. The congress offers almost 200 sessions, including keynote lectures, symposia, oral sessions, educational workshops and meet-the-expert session. ECCMID expects approximately 13,000 participants from more than 100 countries.
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is a non-profit organization dedicated to improving the diagnosis, treatment and prevention of infectious diseases in Europe and beyond. The society promotes and supports research, education, training and good medical practice in infection-related disciplines with a special focus on antimicrobial resistance to build capacity throughout the world. http://www.escmid.org
ESCMID Communications Manager
ESCMID Executive Office
P.O. Box 214, CH-4010 Basel
Phone +41 61 508 01 57
Mobile +41 76 588 08 24
Email [email protected]
ECCMID Communications Assistant
Mobile +41 78 705 79 85
Email [email protected]